Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Which Endpoints Matter Most in Transthyretin Amyloid Cardiomyopathy Trials? Are We Comparing Apples to Apples?

Which Endpoints Matter Most in Transthyretin Amyloid Cardiomyopathy Trials? Are We Comparing Apples to Apples?

FromKeeping Current CME


Which Endpoints Matter Most in Transthyretin Amyloid Cardiomyopathy Trials? Are We Comparing Apples to Apples?

FromKeeping Current CME

ratings:
Length:
16 minutes
Released:
Mar 26, 2024
Format:
Podcast episode

Description

Do you know how to interpret the results of recent phase 3 clinical trials in patients with transthyretin amyloid cardiomyopathy (ATTR-CM)? Credit available for this activity expires: 3/22/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1000444?ecd=bdc_podcast_libsyn_mscpedu
Released:
Mar 26, 2024
Format:
Podcast episode

Titles in the series (100)

Hear from experts as they discuss timely clinical topics as well as relevant and actionable strategies for practice improvement. This podcast is available for CME credit.